Co-Authors
This is a "connection" page, showing publications co-authored by RAVIN RATAN and NEETA SOMAIAH.
Connection Strength
1.966
-
Utility of Clinical Next Generation Sequencing Tests in KIT/PDGFRA/SDH Wild-Type Gastrointestinal Stromal Tumors. Cancers (Basel). 2024 Apr 27; 16(9).
Score: 0.240
-
Outcomes of Late-Line Systemic Treatment in GIST: Does Sequence Matter? Cancers (Basel). 2024 Feb 23; 16(5).
Score: 0.237
-
A randomized, non-comparative phase 2 study of neoadjuvant immune-checkpoint blockade in retroperitoneal dedifferentiated liposarcoma and extremity/truncal undifferentiated pleomorphic sarcoma. Nat Cancer. 2024 Apr; 5(4):625-641.
Score: 0.237
-
Retrospective evaluation of the role of gemcitabine-docetaxel in well-differentiated and dedifferentiated liposarcoma. Cancer Med. 2023 02; 12(4):4282-4293.
Score: 0.215
-
Outcomes of systemic therapy in metastatic phyllodes tumor of the breast. Breast Cancer Res Treat. 2021 Apr; 186(3):871-882.
Score: 0.192
-
PET/CT Imaging as a Diagnostic Tool in Distinguishing Well-Differentiated versus Dedifferentiated Liposarcoma. Sarcoma. 2020; 2020:8363986.
Score: 0.183
-
Moderately hypofractionated, preoperative radiotherapy in patients with soft tissue sarcomas (HYPORT-STS): Updated local control, late toxicities, and patient-reported outcomes. Cancer. 2024 Aug 27.
Score: 0.061
-
Clinical characteristics and outcomes of adult alveolar rhabdomyosarcoma patients on first-line systemic therapies: A single-institution cohort. Rare Tumors. 2024; 16:20363613241271669.
Score: 0.061
-
High-Grade Pleomorphic Sarcomas Treated with Immune Checkpoint Blockade: The MD Anderson Cancer Center Experience. Cancers (Basel). 2024 May 01; 16(9).
Score: 0.060
-
Safety and efficacy of percutaneous image-guided ablation for soft tissue sarcoma metastases to the liver. Cancer. 2024 Aug 01; 130(15):2703-2712.
Score: 0.060
-
SABR for Sarcoma Lung Metastases: Indications for Treatment and Guidance for Patient Selection. Int J Radiat Oncol Biol Phys. 2024 Mar 15; 118(4):971-978.
Score: 0.058
-
Impact of Biomarker-Matched Therapies on Outcomes in Patients with Sarcoma Enrolled in Early-Phase Clinical Trials (SAMBA 101). Clin Cancer Res. 2023 05 01; 29(9):1708-1718.
Score: 0.056
-
Examining Stripes on a Herd of Zebras: Impact of Genomic Matching for Ultrarare Sarcomas in Phase 1 Clinical Trials (SAMBA 102). Clin Cancer Res. 2023 01 17; 29(2):401-409.
Score: 0.055
-
Hypofractionated, 3-week, preoperative radiotherapy for patients with soft tissue sarcomas (HYPORT-STS): a single-centre, open-label, single-arm, phase 2 trial. Lancet Oncol. 2022 12; 23(12):1547-1557.
Score: 0.054
-
The immune landscape of undifferentiated pleomorphic sarcoma. Front Oncol. 2022; 12:1008484.
Score: 0.054
-
Systemic Chemotherapies Retain Antitumor Activity in Desmoid Tumors Independent of Specific Mutations in CTNNB1 or APC: A Multi-institutional Retrospective Study. Clin Cancer Res. 2022 09 15; 28(18):4092-4104.
Score: 0.054
-
Hypofractionated Radiation Therapy for Unresectable or Metastatic Sarcoma Lesions. Adv Radiat Oncol. 2022 May-Jun; 7(3):100913.
Score: 0.051
-
Vincristine, Ifosfamide, and Doxorubicin for Initial Treatment of Ewing Sarcoma in Adults. Oncologist. 2017 10; 22(10):1271-1277.
Score: 0.037